21 results
Thumbnail

D1.396 - Drug hypersensitivity reactions in paediatric patients pre and post-liver transplant: a single-center study

Thumbnail

D1.394 - Functional AOC1 variants associated with reduced diamine oxidase activity mimicking multiple drug hypersensitivity and mast cell disorders

Thumbnail

D1.397 - Successfull rapid drug desensitization to cemiplimab in a patient with lung squamous cell carcinoma

Thumbnail

D1.398 - Safety Outcomes and Predictors of Clinically Significant Reactions in Positive Drug Provocation Tests: A 10-Year Tertiary-Center Cohort

Thumbnail

D1.399 - Selective IgE Mediated Anaphylaxis to Gadobutrol and type I Kounis with tolerance to Gadoxetate Disodium

Thumbnail

D1.400 - Omalizumab premedication improves ferric carboxymaltose desensitization outcomes: A Case Report

Thumbnail

D1.401 - Progression from Immediate to Delayed Hypersensitivity: A Rare Case of Iodixanol-Induced Acute Generalised Exanthematous Pustulosis

Thumbnail

D1.402 - Angiotensin-Converting Enzyme Inhibitor–Induced Bradykinin-Mediated Angioedema: Three Cases of Sustained Remission Following Definitive Discontinuation and the Critical Role of the Prescribing Physician

Thumbnail

D2.471 - Efficacy of omalizumab in the treatment of chronic spontaneous urticaria in children

Thumbnail

D2.473 - Omalizumab as adjuvant therapy in drug desensitization to chemotherapy- a single Center experience

Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.464 - Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.470 - Potential Clinical and Laboratory Biomarkers for Predicting Omalizumab Response in Chronic Spontaneous Urticaria

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report